nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2C8—Sorafenib—thyroid cancer	0.114	0.19	CbGbCtD
Levomilnacipran—CYP2C19—Sorafenib—thyroid cancer	0.0957	0.159	CbGbCtD
Levomilnacipran—ABCB1—Sorafenib—thyroid cancer	0.0772	0.128	CbGbCtD
Levomilnacipran—CYP3A4—Vandetanib—thyroid cancer	0.0767	0.128	CbGbCtD
Levomilnacipran—CYP2D6—Sorafenib—thyroid cancer	0.0727	0.121	CbGbCtD
Levomilnacipran—ABCB1—Doxorubicin—thyroid cancer	0.0468	0.0778	CbGbCtD
Levomilnacipran—CYP3A4—Sorafenib—thyroid cancer	0.0463	0.0769	CbGbCtD
Levomilnacipran—CYP2D6—Doxorubicin—thyroid cancer	0.0441	0.0734	CbGbCtD
Levomilnacipran—CYP3A4—Doxorubicin—thyroid cancer	0.0281	0.0466	CbGbCtD
Levomilnacipran—Weight decreased—Sorafenib—thyroid cancer	0.00211	0.00529	CcSEcCtD
Levomilnacipran—Convulsion—Vandetanib—thyroid cancer	0.00208	0.00523	CcSEcCtD
Levomilnacipran—Hypertension—Vandetanib—thyroid cancer	0.00208	0.00521	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00206	0.00517	CcSEcCtD
Levomilnacipran—Chest pain—Vandetanib—thyroid cancer	0.00205	0.00514	CcSEcCtD
Levomilnacipran—Anxiety—Vandetanib—thyroid cancer	0.00204	0.00512	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00203	0.0051	CcSEcCtD
Levomilnacipran—Dry mouth—Vandetanib—thyroid cancer	0.002	0.00503	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00196	0.00493	CcSEcCtD
Levomilnacipran—Infection—Vandetanib—thyroid cancer	0.00195	0.00489	CcSEcCtD
Levomilnacipran—Nervous system disorder—Vandetanib—thyroid cancer	0.00192	0.00483	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Vandetanib—thyroid cancer	0.00192	0.00482	CcSEcCtD
Levomilnacipran—Skin disorder—Vandetanib—thyroid cancer	0.00191	0.00478	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Sorafenib—thyroid cancer	0.00184	0.00462	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Sorafenib—thyroid cancer	0.00183	0.0046	CcSEcCtD
Levomilnacipran—Urethral disorder—Sorafenib—thyroid cancer	0.00183	0.00458	CcSEcCtD
Levomilnacipran—Insomnia—Vandetanib—thyroid cancer	0.00177	0.00446	CcSEcCtD
Levomilnacipran—Paraesthesia—Vandetanib—thyroid cancer	0.00176	0.00442	CcSEcCtD
Levomilnacipran—Erythema multiforme—Sorafenib—thyroid cancer	0.00176	0.00442	CcSEcCtD
Levomilnacipran—Dyspnoea—Vandetanib—thyroid cancer	0.00175	0.00439	CcSEcCtD
Levomilnacipran—Flushing—Sorafenib—thyroid cancer	0.00173	0.00434	CcSEcCtD
Levomilnacipran—Cardiac disorder—Sorafenib—thyroid cancer	0.00173	0.00434	CcSEcCtD
Levomilnacipran—Dyspepsia—Vandetanib—thyroid cancer	0.00173	0.00434	CcSEcCtD
Levomilnacipran—Decreased appetite—Vandetanib—thyroid cancer	0.00171	0.00428	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00169	0.00425	CcSEcCtD
Levomilnacipran—Fatigue—Vandetanib—thyroid cancer	0.00169	0.00425	CcSEcCtD
Levomilnacipran—Angiopathy—Sorafenib—thyroid cancer	0.00169	0.00424	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Sorafenib—thyroid cancer	0.00168	0.00422	CcSEcCtD
Levomilnacipran—Constipation—Vandetanib—thyroid cancer	0.00168	0.00421	CcSEcCtD
Levomilnacipran—Mental disorder—Sorafenib—thyroid cancer	0.00163	0.0041	CcSEcCtD
Levomilnacipran—Malnutrition—Sorafenib—thyroid cancer	0.00162	0.00407	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Vandetanib—thyroid cancer	0.0016	0.00403	CcSEcCtD
Levomilnacipran—Delirium—Epirubicin—thyroid cancer	0.00159	0.004	CcSEcCtD
Levomilnacipran—Dysgeusia—Sorafenib—thyroid cancer	0.00159	0.00399	CcSEcCtD
Levomilnacipran—Abdominal pain—Vandetanib—thyroid cancer	0.00155	0.00389	CcSEcCtD
Levomilnacipran—Body temperature increased—Vandetanib—thyroid cancer	0.00155	0.00389	CcSEcCtD
Levomilnacipran—Ventricular extrasystoles—Epirubicin—thyroid cancer	0.00152	0.00381	CcSEcCtD
Levomilnacipran—Delirium—Doxorubicin—thyroid cancer	0.00148	0.0037	CcSEcCtD
Levomilnacipran—Syncope—Sorafenib—thyroid cancer	0.00145	0.00365	CcSEcCtD
Levomilnacipran—Leukopenia—Sorafenib—thyroid cancer	0.00145	0.00364	CcSEcCtD
Levomilnacipran—Loss of consciousness—Sorafenib—thyroid cancer	0.00143	0.00358	CcSEcCtD
Levomilnacipran—Asthenia—Vandetanib—thyroid cancer	0.00141	0.00353	CcSEcCtD
Levomilnacipran—Ventricular extrasystoles—Doxorubicin—thyroid cancer	0.0014	0.00353	CcSEcCtD
Levomilnacipran—Hypertension—Sorafenib—thyroid cancer	0.0014	0.00352	CcSEcCtD
Levomilnacipran—Pruritus—Vandetanib—thyroid cancer	0.00139	0.00349	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00137	0.00344	CcSEcCtD
Levomilnacipran—Dry mouth—Sorafenib—thyroid cancer	0.00135	0.00339	CcSEcCtD
Levomilnacipran—Diarrhoea—Vandetanib—thyroid cancer	0.00134	0.00337	CcSEcCtD
Levomilnacipran—Cystitis noninfective—Epirubicin—thyroid cancer	0.00134	0.00336	CcSEcCtD
Levomilnacipran—Cystitis—Epirubicin—thyroid cancer	0.00132	0.00332	CcSEcCtD
Levomilnacipran—Infection—Sorafenib—thyroid cancer	0.00132	0.0033	CcSEcCtD
Levomilnacipran—Shock—Sorafenib—thyroid cancer	0.0013	0.00327	CcSEcCtD
Levomilnacipran—Nervous system disorder—Sorafenib—thyroid cancer	0.0013	0.00326	CcSEcCtD
Levomilnacipran—Dizziness—Vandetanib—thyroid cancer	0.0013	0.00326	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Sorafenib—thyroid cancer	0.0013	0.00325	CcSEcCtD
Levomilnacipran—Skin disorder—Sorafenib—thyroid cancer	0.00129	0.00323	CcSEcCtD
Levomilnacipran—Dry eye—Epirubicin—thyroid cancer	0.00127	0.00318	CcSEcCtD
Levomilnacipran—Anorexia—Sorafenib—thyroid cancer	0.00126	0.00317	CcSEcCtD
Levomilnacipran—Vomiting—Vandetanib—thyroid cancer	0.00125	0.00313	CcSEcCtD
Levomilnacipran—Bladder pain—Epirubicin—thyroid cancer	0.00124	0.00311	CcSEcCtD
Levomilnacipran—Cystitis noninfective—Doxorubicin—thyroid cancer	0.00124	0.00311	CcSEcCtD
Levomilnacipran—Rash—Vandetanib—thyroid cancer	0.00124	0.00311	CcSEcCtD
Levomilnacipran—Dermatitis—Vandetanib—thyroid cancer	0.00124	0.0031	CcSEcCtD
Levomilnacipran—Headache—Vandetanib—thyroid cancer	0.00123	0.00309	CcSEcCtD
Levomilnacipran—Cystitis—Doxorubicin—thyroid cancer	0.00123	0.00308	CcSEcCtD
Levomilnacipran—Dyspnoea—Sorafenib—thyroid cancer	0.00118	0.00296	CcSEcCtD
Levomilnacipran—Dry eye—Doxorubicin—thyroid cancer	0.00117	0.00294	CcSEcCtD
Levomilnacipran—Nausea—Vandetanib—thyroid cancer	0.00117	0.00293	CcSEcCtD
Levomilnacipran—Dyspepsia—Sorafenib—thyroid cancer	0.00117	0.00293	CcSEcCtD
Levomilnacipran—Decreased appetite—Sorafenib—thyroid cancer	0.00115	0.00289	CcSEcCtD
Levomilnacipran—Bladder pain—Doxorubicin—thyroid cancer	0.00115	0.00288	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00114	0.00287	CcSEcCtD
Levomilnacipran—Fatigue—Sorafenib—thyroid cancer	0.00114	0.00286	CcSEcCtD
Levomilnacipran—Constipation—Sorafenib—thyroid cancer	0.00113	0.00284	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00108	0.00272	CcSEcCtD
Levomilnacipran—Renal failure acute—Epirubicin—thyroid cancer	0.00108	0.00271	CcSEcCtD
Levomilnacipran—Hot flush—Epirubicin—thyroid cancer	0.00106	0.00267	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Epirubicin—thyroid cancer	0.00105	0.00265	CcSEcCtD
Levomilnacipran—Urticaria—Sorafenib—thyroid cancer	0.00105	0.00264	CcSEcCtD
Levomilnacipran—Body temperature increased—Sorafenib—thyroid cancer	0.00105	0.00263	CcSEcCtD
Levomilnacipran—Abdominal pain—Sorafenib—thyroid cancer	0.00105	0.00263	CcSEcCtD
Levomilnacipran—Hyponatraemia—Epirubicin—thyroid cancer	0.000999	0.00251	CcSEcCtD
Levomilnacipran—Renal failure acute—Doxorubicin—thyroid cancer	0.000998	0.0025	CcSEcCtD
Levomilnacipran—Hot flush—Doxorubicin—thyroid cancer	0.000985	0.00247	CcSEcCtD
Levomilnacipran—Migraine—Epirubicin—thyroid cancer	0.00098	0.00246	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000976	0.00245	CcSEcCtD
Levomilnacipran—Hypersensitivity—Sorafenib—thyroid cancer	0.000975	0.00245	CcSEcCtD
Levomilnacipran—Asthenia—Sorafenib—thyroid cancer	0.00095	0.00238	CcSEcCtD
Levomilnacipran—Pruritus—Sorafenib—thyroid cancer	0.000937	0.00235	CcSEcCtD
Levomilnacipran—Hyponatraemia—Doxorubicin—thyroid cancer	0.000925	0.00232	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Epirubicin—thyroid cancer	0.000919	0.00231	CcSEcCtD
Levomilnacipran—Dry skin—Epirubicin—thyroid cancer	0.000912	0.00229	CcSEcCtD
Levomilnacipran—Migraine—Doxorubicin—thyroid cancer	0.000906	0.00228	CcSEcCtD
Levomilnacipran—Diarrhoea—Sorafenib—thyroid cancer	0.000906	0.00227	CcSEcCtD
Levomilnacipran—Breast disorder—Epirubicin—thyroid cancer	0.000899	0.00226	CcSEcCtD
Levomilnacipran—Dizziness—Sorafenib—thyroid cancer	0.000875	0.0022	CcSEcCtD
Levomilnacipran—Abdominal distension—Epirubicin—thyroid cancer	0.000866	0.00217	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00085	0.00213	CcSEcCtD
Levomilnacipran—Dry skin—Doxorubicin—thyroid cancer	0.000844	0.00212	CcSEcCtD
Levomilnacipran—Vomiting—Sorafenib—thyroid cancer	0.000842	0.00211	CcSEcCtD
Levomilnacipran—Angina pectoris—Epirubicin—thyroid cancer	0.000838	0.0021	CcSEcCtD
Levomilnacipran—Rash—Sorafenib—thyroid cancer	0.000835	0.0021	CcSEcCtD
Levomilnacipran—Dermatitis—Sorafenib—thyroid cancer	0.000834	0.00209	CcSEcCtD
Levomilnacipran—Breast disorder—Doxorubicin—thyroid cancer	0.000832	0.00209	CcSEcCtD
Levomilnacipran—Headache—Sorafenib—thyroid cancer	0.000829	0.00208	CcSEcCtD
Levomilnacipran—Dysuria—Epirubicin—thyroid cancer	0.000804	0.00202	CcSEcCtD
Levomilnacipran—Neutropenia—Epirubicin—thyroid cancer	0.000804	0.00202	CcSEcCtD
Levomilnacipran—Abdominal distension—Doxorubicin—thyroid cancer	0.000801	0.00201	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.0008	0.00201	CcSEcCtD
Levomilnacipran—Pollakiuria—Epirubicin—thyroid cancer	0.000795	0.00199	CcSEcCtD
Levomilnacipran—Nausea—Sorafenib—thyroid cancer	0.000786	0.00197	CcSEcCtD
Levomilnacipran—Weight decreased—Epirubicin—thyroid cancer	0.000778	0.00195	CcSEcCtD
Levomilnacipran—Angina pectoris—Doxorubicin—thyroid cancer	0.000775	0.00195	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00076	0.00191	CcSEcCtD
Levomilnacipran—Urinary tract infection—Epirubicin—thyroid cancer	0.000746	0.00187	CcSEcCtD
Levomilnacipran—Dysuria—Doxorubicin—thyroid cancer	0.000744	0.00187	CcSEcCtD
Levomilnacipran—Neutropenia—Doxorubicin—thyroid cancer	0.000744	0.00187	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00074	0.00186	CcSEcCtD
Levomilnacipran—Pollakiuria—Doxorubicin—thyroid cancer	0.000735	0.00185	CcSEcCtD
Levomilnacipran—Haematuria—Epirubicin—thyroid cancer	0.000731	0.00184	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000725	0.00182	CcSEcCtD
Levomilnacipran—Weight decreased—Doxorubicin—thyroid cancer	0.00072	0.00181	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000704	0.00177	CcSEcCtD
Levomilnacipran—Urinary tract infection—Doxorubicin—thyroid cancer	0.00069	0.00173	CcSEcCtD
Levomilnacipran—Hepatitis—Epirubicin—thyroid cancer	0.000689	0.00173	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Epirubicin—thyroid cancer	0.000685	0.00172	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Epirubicin—thyroid cancer	0.00068	0.00171	CcSEcCtD
Levomilnacipran—Oedema peripheral—Epirubicin—thyroid cancer	0.000678	0.0017	CcSEcCtD
Levomilnacipran—Haematuria—Doxorubicin—thyroid cancer	0.000677	0.0017	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Epirubicin—thyroid cancer	0.000677	0.0017	CcSEcCtD
Levomilnacipran—Urethral disorder—Epirubicin—thyroid cancer	0.000675	0.00169	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000671	0.00169	CcSEcCtD
Levomilnacipran—Erythema multiforme—Epirubicin—thyroid cancer	0.000651	0.00163	CcSEcCtD
Levomilnacipran—Eye disorder—Epirubicin—thyroid cancer	0.000643	0.00162	CcSEcCtD
Levomilnacipran—Flushing—Epirubicin—thyroid cancer	0.000639	0.0016	CcSEcCtD
Levomilnacipran—Cardiac disorder—Epirubicin—thyroid cancer	0.000639	0.0016	CcSEcCtD
Levomilnacipran—Hepatitis—Doxorubicin—thyroid cancer	0.000637	0.0016	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000634	0.00159	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000629	0.00158	CcSEcCtD
Levomilnacipran—Oedema peripheral—Doxorubicin—thyroid cancer	0.000628	0.00158	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000626	0.00157	CcSEcCtD
Levomilnacipran—Angiopathy—Epirubicin—thyroid cancer	0.000625	0.00157	CcSEcCtD
Levomilnacipran—Urethral disorder—Doxorubicin—thyroid cancer	0.000625	0.00157	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Epirubicin—thyroid cancer	0.000621	0.00156	CcSEcCtD
Levomilnacipran—Chills—Epirubicin—thyroid cancer	0.000618	0.00155	CcSEcCtD
Levomilnacipran—Mental disorder—Epirubicin—thyroid cancer	0.000603	0.00151	CcSEcCtD
Levomilnacipran—Erythema multiforme—Doxorubicin—thyroid cancer	0.000602	0.00151	CcSEcCtD
Levomilnacipran—Malnutrition—Epirubicin—thyroid cancer	0.000599	0.0015	CcSEcCtD
Levomilnacipran—Eye disorder—Doxorubicin—thyroid cancer	0.000595	0.00149	CcSEcCtD
Levomilnacipran—Cardiac disorder—Doxorubicin—thyroid cancer	0.000591	0.00148	CcSEcCtD
Levomilnacipran—Flushing—Doxorubicin—thyroid cancer	0.000591	0.00148	CcSEcCtD
Levomilnacipran—Flatulence—Epirubicin—thyroid cancer	0.000591	0.00148	CcSEcCtD
Levomilnacipran—Tension—Epirubicin—thyroid cancer	0.000588	0.00148	CcSEcCtD
Levomilnacipran—Dysgeusia—Epirubicin—thyroid cancer	0.000587	0.00147	CcSEcCtD
Levomilnacipran—Angiopathy—Doxorubicin—thyroid cancer	0.000578	0.00145	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000574	0.00144	CcSEcCtD
Levomilnacipran—Chills—Doxorubicin—thyroid cancer	0.000572	0.00144	CcSEcCtD
Levomilnacipran—Vision blurred—Epirubicin—thyroid cancer	0.000565	0.00142	CcSEcCtD
Levomilnacipran—Mental disorder—Doxorubicin—thyroid cancer	0.000558	0.0014	CcSEcCtD
Levomilnacipran—Malnutrition—Doxorubicin—thyroid cancer	0.000555	0.00139	CcSEcCtD
Levomilnacipran—Agitation—Epirubicin—thyroid cancer	0.000551	0.00138	CcSEcCtD
Levomilnacipran—Flatulence—Doxorubicin—thyroid cancer	0.000547	0.00137	CcSEcCtD
Levomilnacipran—Tension—Doxorubicin—thyroid cancer	0.000544	0.00137	CcSEcCtD
Levomilnacipran—Dysgeusia—Doxorubicin—thyroid cancer	0.000543	0.00136	CcSEcCtD
Levomilnacipran—Syncope—Epirubicin—thyroid cancer	0.000538	0.00135	CcSEcCtD
Levomilnacipran—Leukopenia—Epirubicin—thyroid cancer	0.000537	0.00135	CcSEcCtD
Levomilnacipran—Palpitations—Epirubicin—thyroid cancer	0.00053	0.00133	CcSEcCtD
Levomilnacipran—Loss of consciousness—Epirubicin—thyroid cancer	0.000527	0.00132	CcSEcCtD
Levomilnacipran—Vision blurred—Doxorubicin—thyroid cancer	0.000523	0.00131	CcSEcCtD
Levomilnacipran—Convulsion—Epirubicin—thyroid cancer	0.000519	0.0013	CcSEcCtD
Levomilnacipran—Hypertension—Epirubicin—thyroid cancer	0.000518	0.0013	CcSEcCtD
Levomilnacipran—Chest pain—Epirubicin—thyroid cancer	0.00051	0.00128	CcSEcCtD
Levomilnacipran—Agitation—Doxorubicin—thyroid cancer	0.00051	0.00128	CcSEcCtD
Levomilnacipran—Anxiety—Epirubicin—thyroid cancer	0.000509	0.00128	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000507	0.00127	CcSEcCtD
Levomilnacipran—Dry mouth—Epirubicin—thyroid cancer	0.000499	0.00125	CcSEcCtD
Levomilnacipran—Syncope—Doxorubicin—thyroid cancer	0.000497	0.00125	CcSEcCtD
Levomilnacipran—Leukopenia—Doxorubicin—thyroid cancer	0.000496	0.00125	CcSEcCtD
Levomilnacipran—Palpitations—Doxorubicin—thyroid cancer	0.00049	0.00123	CcSEcCtD
Levomilnacipran—Loss of consciousness—Doxorubicin—thyroid cancer	0.000487	0.00122	CcSEcCtD
Levomilnacipran—Infection—Epirubicin—thyroid cancer	0.000486	0.00122	CcSEcCtD
Levomilnacipran—Shock—Epirubicin—thyroid cancer	0.000481	0.00121	CcSEcCtD
Levomilnacipran—Convulsion—Doxorubicin—thyroid cancer	0.000481	0.00121	CcSEcCtD
Levomilnacipran—Nervous system disorder—Epirubicin—thyroid cancer	0.00048	0.0012	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Epirubicin—thyroid cancer	0.000479	0.0012	CcSEcCtD
Levomilnacipran—Hypertension—Doxorubicin—thyroid cancer	0.000479	0.0012	CcSEcCtD
Levomilnacipran—Tachycardia—Epirubicin—thyroid cancer	0.000477	0.0012	CcSEcCtD
Levomilnacipran—Skin disorder—Epirubicin—thyroid cancer	0.000475	0.00119	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Epirubicin—thyroid cancer	0.000473	0.00119	CcSEcCtD
Levomilnacipran—Chest pain—Doxorubicin—thyroid cancer	0.000472	0.00119	CcSEcCtD
Levomilnacipran—Anxiety—Doxorubicin—thyroid cancer	0.000471	0.00118	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000469	0.00118	CcSEcCtD
Levomilnacipran—Anorexia—Epirubicin—thyroid cancer	0.000466	0.00117	CcSEcCtD
Levomilnacipran—Dry mouth—Doxorubicin—thyroid cancer	0.000462	0.00116	CcSEcCtD
Levomilnacipran—Hypotension—Epirubicin—thyroid cancer	0.000457	0.00115	CcSEcCtD
Levomilnacipran—Infection—Doxorubicin—thyroid cancer	0.00045	0.00113	CcSEcCtD
Levomilnacipran—Shock—Doxorubicin—thyroid cancer	0.000445	0.00112	CcSEcCtD
Levomilnacipran—Nervous system disorder—Doxorubicin—thyroid cancer	0.000444	0.00111	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000443	0.00111	CcSEcCtD
Levomilnacipran—Insomnia—Epirubicin—thyroid cancer	0.000442	0.00111	CcSEcCtD
Levomilnacipran—Tachycardia—Doxorubicin—thyroid cancer	0.000442	0.00111	CcSEcCtD
Levomilnacipran—Skin disorder—Doxorubicin—thyroid cancer	0.00044	0.0011	CcSEcCtD
Levomilnacipran—Paraesthesia—Epirubicin—thyroid cancer	0.000439	0.0011	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000438	0.0011	CcSEcCtD
Levomilnacipran—Dyspnoea—Epirubicin—thyroid cancer	0.000436	0.00109	CcSEcCtD
Levomilnacipran—Somnolence—Epirubicin—thyroid cancer	0.000435	0.00109	CcSEcCtD
Levomilnacipran—Anorexia—Doxorubicin—thyroid cancer	0.000431	0.00108	CcSEcCtD
Levomilnacipran—Dyspepsia—Epirubicin—thyroid cancer	0.000431	0.00108	CcSEcCtD
Levomilnacipran—Decreased appetite—Epirubicin—thyroid cancer	0.000425	0.00107	CcSEcCtD
Levomilnacipran—Hypotension—Doxorubicin—thyroid cancer	0.000423	0.00106	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000422	0.00106	CcSEcCtD
Levomilnacipran—Fatigue—Epirubicin—thyroid cancer	0.000422	0.00106	CcSEcCtD
Levomilnacipran—Constipation—Epirubicin—thyroid cancer	0.000418	0.00105	CcSEcCtD
Levomilnacipran—Insomnia—Doxorubicin—thyroid cancer	0.000409	0.00103	CcSEcCtD
Levomilnacipran—Paraesthesia—Doxorubicin—thyroid cancer	0.000406	0.00102	CcSEcCtD
Levomilnacipran—Dyspnoea—Doxorubicin—thyroid cancer	0.000404	0.00101	CcSEcCtD
Levomilnacipran—Somnolence—Doxorubicin—thyroid cancer	0.000402	0.00101	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Epirubicin—thyroid cancer	0.0004	0.001	CcSEcCtD
Levomilnacipran—Dyspepsia—Doxorubicin—thyroid cancer	0.000398	0.001	CcSEcCtD
Levomilnacipran—Decreased appetite—Doxorubicin—thyroid cancer	0.000393	0.000988	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000391	0.000981	CcSEcCtD
Levomilnacipran—Fatigue—Doxorubicin—thyroid cancer	0.00039	0.00098	CcSEcCtD
Levomilnacipran—Urticaria—Epirubicin—thyroid cancer	0.000389	0.000976	CcSEcCtD
Levomilnacipran—Constipation—Doxorubicin—thyroid cancer	0.000387	0.000972	CcSEcCtD
Levomilnacipran—Abdominal pain—Epirubicin—thyroid cancer	0.000387	0.000971	CcSEcCtD
Levomilnacipran—Body temperature increased—Epirubicin—thyroid cancer	0.000387	0.000971	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00037	0.000929	CcSEcCtD
Levomilnacipran—Hypersensitivity—Epirubicin—thyroid cancer	0.00036	0.000905	CcSEcCtD
Levomilnacipran—Urticaria—Doxorubicin—thyroid cancer	0.00036	0.000903	CcSEcCtD
Levomilnacipran—Body temperature increased—Doxorubicin—thyroid cancer	0.000358	0.000898	CcSEcCtD
Levomilnacipran—Abdominal pain—Doxorubicin—thyroid cancer	0.000358	0.000898	CcSEcCtD
Levomilnacipran—Asthenia—Epirubicin—thyroid cancer	0.000351	0.000881	CcSEcCtD
Levomilnacipran—Pruritus—Epirubicin—thyroid cancer	0.000346	0.000869	CcSEcCtD
Levomilnacipran—Diarrhoea—Epirubicin—thyroid cancer	0.000335	0.00084	CcSEcCtD
Levomilnacipran—Hypersensitivity—Doxorubicin—thyroid cancer	0.000333	0.000837	CcSEcCtD
Levomilnacipran—Asthenia—Doxorubicin—thyroid cancer	0.000325	0.000815	CcSEcCtD
Levomilnacipran—Dizziness—Epirubicin—thyroid cancer	0.000323	0.000812	CcSEcCtD
Levomilnacipran—Pruritus—Doxorubicin—thyroid cancer	0.00032	0.000804	CcSEcCtD
Levomilnacipran—Vomiting—Epirubicin—thyroid cancer	0.000311	0.000781	CcSEcCtD
Levomilnacipran—Diarrhoea—Doxorubicin—thyroid cancer	0.00031	0.000777	CcSEcCtD
Levomilnacipran—Rash—Epirubicin—thyroid cancer	0.000308	0.000774	CcSEcCtD
Levomilnacipran—Dermatitis—Epirubicin—thyroid cancer	0.000308	0.000774	CcSEcCtD
Levomilnacipran—Headache—Epirubicin—thyroid cancer	0.000306	0.000769	CcSEcCtD
Levomilnacipran—Dizziness—Doxorubicin—thyroid cancer	0.000299	0.000751	CcSEcCtD
Levomilnacipran—Nausea—Epirubicin—thyroid cancer	0.000291	0.000729	CcSEcCtD
Levomilnacipran—Vomiting—Doxorubicin—thyroid cancer	0.000288	0.000722	CcSEcCtD
Levomilnacipran—Rash—Doxorubicin—thyroid cancer	0.000285	0.000716	CcSEcCtD
Levomilnacipran—Dermatitis—Doxorubicin—thyroid cancer	0.000285	0.000716	CcSEcCtD
Levomilnacipran—Headache—Doxorubicin—thyroid cancer	0.000284	0.000712	CcSEcCtD
Levomilnacipran—Nausea—Doxorubicin—thyroid cancer	0.000269	0.000675	CcSEcCtD
